113 related articles for article (PubMed ID: 1456090)
1. Excessive L-thyroxine therapy decreases femoral bone mineral densities in the male rat: effect of hypogonadism and calcitonin.
Ongphiphadhanakul B; Alex S; Braverman LE; Baran DT
J Bone Miner Res; 1992 Oct; 7(10):1227-31. PubMed ID: 1456090
[TBL] [Abstract][Full Text] [Related]
2. [Olpadronate prevents cortical and trabecular bone loss induced by supraphysiological dosis of thyroxine in ovariectomized rats].
Zeni SN; Gómez Acotto C; Di Gregorio S
Medicina (B Aires); 1998; 58(5 Pt 1):453-7. PubMed ID: 9922475
[TBL] [Abstract][Full Text] [Related]
3. Effect of TSH-suppressive doses of levothyroxine on bone mineral density in Thai women.
Ongphiphadhanakul B; Puavilai G; Rajatanavin R
J Med Assoc Thai; 1996 Sep; 79(9):563-7. PubMed ID: 8996984
[TBL] [Abstract][Full Text] [Related]
4. Effects of thyroid hormone administration and estrogen deficiency on bone mass of female rats.
Gouveia CH; Jorgetti V; Bianco AC
J Bone Miner Res; 1997 Dec; 12(12):2098-107. PubMed ID: 9421243
[TBL] [Abstract][Full Text] [Related]
5. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine.
Marcocci C; Golia F; Vignali E; Pinchera A
J Bone Miner Res; 1997 Jan; 12(1):72-7. PubMed ID: 9240728
[TBL] [Abstract][Full Text] [Related]
6. Early induction of alterations in cancellous and cortical bone histology after orchiectomy in mature rats.
Gunness M; Orwoll E
J Bone Miner Res; 1995 Nov; 10(11):1735-44. PubMed ID: 8592951
[TBL] [Abstract][Full Text] [Related]
7. A rat model of thyroid hormone-induced bone loss: effect of antiresorptive agents on regional bone density and osteocalcin gene expression.
Kung AW; Ng F
Thyroid; 1994; 4(1):93-8. PubMed ID: 8054866
[TBL] [Abstract][Full Text] [Related]
8. Bone mineral density during maintenance treatment with supraphysiological doses of levothyroxine in affective disorders: a longitudinal study.
Bauer M; Fairbanks L; Berghöfer A; Hierholzer J; Bschor T; Baethge C; Rasgon N; Sasse J; Whybrow PC
J Affect Disord; 2004 Dec; 83(2-3):183-90. PubMed ID: 15555712
[TBL] [Abstract][Full Text] [Related]
9. Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat.
Ke HZ; Qi H; Crawford DT; Chidsey-Frink KL; Simmons HA; Thompson DD
Endocrinology; 2000 Apr; 141(4):1338-44. PubMed ID: 10746637
[TBL] [Abstract][Full Text] [Related]
10. [Effects of teriparatide and alendronate on bone mineral density of osteoporotic rats].
Li M; Jiao J; Meng XW; Xing XP; Xia WB; Zhou XY; Liu HC; Jiang Y; Wang O; Hu YY; Zhan ZW
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(5):335-8. PubMed ID: 15854512
[TBL] [Abstract][Full Text] [Related]
11. Changes of bone mineral density in pre-menopausal women with differentiated thyroid cancer receiving L-thyroxine suppressive therapy.
Mazokopakis EE; Starakis IK; Papadomanolaki MG; Batistakis AG; Papadakis JA
Curr Med Res Opin; 2006 Jul; 22(7):1369-73. PubMed ID: 16834835
[TBL] [Abstract][Full Text] [Related]
12. [Bone density in differentiated cancer of the thyroid gland treated by hormone-suppressive therapy. Study based on 51 cases].
Eulry F; Bauduceau B; Lechevalier D; Magnin J; Crozes P; Flageat J; Gautier D
Rev Rhum Mal Osteoartic; 1992 Apr; 59(4):247-52. PubMed ID: 1496271
[TBL] [Abstract][Full Text] [Related]
13. Effect of growth hormone on bone: bone mineral density, trabecular bone volume, and alkaline phosphatase improve or are restored in the dwarf rat treated with growth hormone.
Wright NM; Renault J; Hollis B; Bell NH; Key LL
J Bone Miner Res; 1995 Jan; 10(1):127-31. PubMed ID: 7747619
[TBL] [Abstract][Full Text] [Related]
14. Prostaglandin E2 administration prevents bone loss induced by orchidectomy in rats.
Li M; Jee WS; Ke HZ; Tang LY; Ma YF; Liang XG; Setterberg RB
J Bone Miner Res; 1995 Jan; 10(1):66-73. PubMed ID: 7747632
[TBL] [Abstract][Full Text] [Related]
15. Etidronate inhibits the thyroid hormone-induced bone loss in rats assessed by bone mineral density and messenger ribonucleic acid markers of osteoblast and osteoclast function.
Ongphiphadhanakul B; Jenis LG; Braverman LE; Alex S; Stein GS; Lian JB; Baran DT
Endocrinology; 1993 Dec; 133(6):2502-7. PubMed ID: 8243271
[TBL] [Abstract][Full Text] [Related]
16. Supplementation of L-arginine prevents glucocorticoid-induced reduction of bone growth and bone turnover abnormalities in a growing rat model.
Pennisi P; D'Alcamo MA; Leonetti C; Clementi A; Cutuli VM; Riccobene S; Parisi N; Fiore CE
J Bone Miner Metab; 2005; 23(2):134-9. PubMed ID: 15750691
[TBL] [Abstract][Full Text] [Related]
17. [Bone mineral density in patients on long-term therapy with levothyroxine].
Korsić M; Cvijetić S; Dekanić-Ozegović D; Bolanća S; Kozić B
Lijec Vjesn; 1998 May; 120(5):103-5. PubMed ID: 9748785
[TBL] [Abstract][Full Text] [Related]
18. Effects of stanozolol on bone mineral density and bone biomechanical properties of osteoporotic rats.
Liao JM; Wu T; Li QN; Hu B; Huang LF; Li ZH; Yuan L; Zhong SZ
Di Yi Jun Yi Da Xue Xue Bao; 2003 Nov; 23(11):1117-20. PubMed ID: 14625163
[TBL] [Abstract][Full Text] [Related]
19. Spared bone mass in rats treated with thyroid hormone receptor TR beta-selective compound GC-1.
Freitas FR; Moriscot AS; Jorgetti V; Soares AG; Passarelli M; Scanlan TS; Brent GA; Bianco AC; Gouveia CH
Am J Physiol Endocrinol Metab; 2003 Nov; 285(5):E1135-41. PubMed ID: 12965872
[TBL] [Abstract][Full Text] [Related]
20. Abnormalities in bone mineral density distribution and bone scintigraphy in patients with childhood onset hypopituitarism.
Kosowicz J; El Ali Z; Ziemnicka K; Sowinski J
J Clin Densitom; 2007; 10(3):332-9. PubMed ID: 17470407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
